Get funding and support for your longevity science research

VitaDAO funds translational R&D projects with a view to commercialization of the resulting IP. Join an engaged community of researchers, technologists, and funding partners who are here to support you from application, to project funding and beyond.

A faster and more efficient path to funding

Our Dealflow team ensures a swift and uncomplicated funding process - leaving you more time to focus on research. Funding takes an average of 103 days, and you benefit from a single point of contact throughout.

We back research that
others won’t

We back research that others won’t

We believe in innovative research. VitaDAO is fully independent and self-governed, which means we back highly novel projects that present higher risk, but have the potential to make revolutionary contributions to science.

A community that stands behind your work

Whether you’re applying for funding, looking for feedback, or just want to stay abreast of developments in the field, VitaDAO welcomes you to a skilled and diverse community who are invested in the outcomes of your research.

... and we’re just getting started.

“Assigning an intellectual property agreement to VitaDAO allowed us to concentrate on the wet lab. They talk to industry to see who is willing to buy the IP, or do clinical trials. This is a win-win for both parties.”

Evandro Fei Fang
Evandro Fang Lab, University of Oslo
A few of our partners at the cutting edge of longevity research

VitaDAO funding in more detail

Who Can Apply

We welcome applications from anywhere in the world, and researchers at any stage of their career - including professors, post-docs, research scientists, and even students. We also fund biotech startups!

Research Areas

We are interested in therapeutic interventions that can (a) extend healthy lifespan across species, or (b) treat or prevent multiple age-related diseases where lifespan data is not available.

Deal Terms

Royalties, sub-licenses, sponsored research, co-development agreements, and equity participation are all available as options depending on the nature of your project.


The VitaDAO community has supporters from both public and private funding sources including venture capital. VitaDAO endorsed and funded projects benefit from early access to this network.

Qualifying Projects

We primarily fund translational R&D. Eligible projects should have a plan for developing a new therapeutics or diagnostics to yield patentable Composition of Matter IP with potential commercial value.

Grant Size

Our typical grant size is $250k, covering 1-2 years of R&D. Funding may be lower or higher, but we prioritize lower budgets. Ideally, funding is milestone based, with a frugal budget for a “killer experiment” and more on success.

IP Ownership

In some cases VitaDAO owns the intellectual property from the projects that it funds. In other cases the funded institution and other third parties can maintain partial or full ownership of IP.


Our team of senior researchers, IP attorneys, drug hunters, med chemists, and biotech VCs will support you at every step of the way - from application to funding and comercialization.

More questions? Read our Funding FAQ, or get in touch with our team by emailing

The VitaDAO project timeline — 103 days from application to funding.

ImmuneAge Bio - Rejuvenation of aged HSCs

ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation. ImmuneAGE rejuvenates hematopoietic stem cells (HSCs) from the bone marrow based on a geroscience screening platform enabled by a new ‘StemSupply’ method achieving >1000x expansion of HSCs.

View Project

ApoptoSENS - Senolytic CAR-NK Cells

Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.

$ 253,000
View Project

Discovery of novel mitophagy activators for Alzheimer’s disease

Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.

$ 300,000
View Project

Scheibye-Knudsen Lab

What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.

$ 250,000
View Project
A few of our top scientific contributors
Michael Baran
Michael Baran
Michael Baran, MBA, PHD is Executive Director, WRDM and Partner at Pfizer Ventures
Morten Scheibye-Knudsen
Morten Scheibye-Knudsen
Laboratory founder and leading longevity scientist.
Viktor Korolchuk
Viktor Korolchuk
Reader in Molecular Cell Biology at Newcastle University
Marco Quarta
Marco Quarta
Co-Founder & CEO at Rubedo Life Sciences
Jean M. Herbert
Jean M. Herbert
Neurogeneticist at the Albert Einstein College of Medicine
Vittorio Sebastiano
Vittorio Sebastiano
Associate Professor of Reproductive and Stem Cell Biology at Stanford

Are you working on the next longevity science breakthrough?

Get involved with more VitaDAO initiatives

The Longevity Prize

The Longevity prize awards outstanding progress in longevity research — crowdsourced and curated by leading industry experts.

Visit The Website
The Longevity Prize
Collage of people

VitaDAO Fellowship

Funding the future of longevity science through need-based grants up to $3000.

Find Out More

The Longevist

An overlay journal curating the world’s most promising longevity research.

Launching Soon!

The Longevist launching soon

The VitaDAO Genesis hoodie is now available

Order now